Dopamine D2 receptors as treatment targets in schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 4, Issue 1, 2010, Pages 56-73

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; D2 polymorphisms; D2High; D3; Dopamine D2 receptor; Dopamine supersensitivity; Parkinsonism; Schizophrenia

Indexed keywords

4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; AMOXAPINE; ARIPIPRAZOLE; BENPERIDOL; BIFEPRUNOX; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SERTINDOLE; SPIPERONE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPERIDOL; UNINDEXED DRUG; ZIPRASIDONE;

CATALEPSY; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSONIAN DISORDERS; POLYMORPHISM, GENETIC; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 77950581269     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.4.1.5     Document Type: Review

References (160)

1. Seeman P. All psychotic roads lead to increased dopamine D2High receptors: a perspective. Clinical Schizophrenia & Related Psychoses 2008:1(4):351-355.
2. Delay J, Deniker P, Harl JM. [Therapeutic method derived from hiberno-therapy in excitation and agitation states.] Ann Med Psychol (Paris) 1952;110(2:2):267-273. French.
3. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60(12):1228-1235. (Pubitemid 37494076)
4. Agid O, Seeman P, Kapur S. The "delayed onset" of antipsychotic action - an idea whose time has come and gone. J Psychiatry Neurosci 2006;31(2):93-100.
5. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005;162(5):939-946. (Pubitemid 40676207)
6. Melis M, Mereu G, Lilliu V, Quartu M, Diana M, Gessa GL. Haloperidol does not produce dopamine cell depolarization-block in paralyzed, unanesthetized rats. Brain Res 1998;783(1):127-132. (Pubitemid 28131430)
7. Van Rossum JM, Hurkmans AT. Mechanism of action of psychomotor stimulant drugs. Significance of dopamine in locomotor stimulant action. Int J Neuropharmacol 1964;3:227-240.
8. Van Rossum JM. Different types of sympathomimetic alpha-receptors. J Pharm Pharmacol 1965;17:202-216.
9. Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966;160:492-494.
10. Van Rossum JM. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole JO, Deniker P, et al., editors. Neuro-Psycho-Pharmacology: Proceedings of the Fifth International Congress of the Collegium Internationale Neuro-Psycho-Pharmacologicum, 1966 March 28-31; Washington. Amsterdam: Excerpta Medica Foundation; 1967. p. 321-329.
11. Seeman P, Wong M, Lee T. Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. Fedn Proc 1974;33:246.
12. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 1975;72(11):4376-4380.
13. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261(5562):717-719.
14. Snyder SH, Creese I, Burt DR. The brain's dopamine receptor: labeling with [3H]dopamine and [3H]haloperidol. Psychopharmacol Commun 1975;1(6):663-673.
15. Burt DR, Creese I, Snyder SH. Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 1976;12(5):800-812. (Pubitemid 8011598)
16. Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988;336(6201):783-787. (Pubitemid 19014439)
17. Spano PF, Govoni S, Trabucchi M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol 1978;19:155-165.
18. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277(5692):93-96.
19. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990;347(6288):80-83. (Pubitemid 20280184)
20. De Camilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979;278(5701):252-254. (Pubitemid 9129071)
21. Meunier H, Labrie F. The dopamine receptor in the intermediate lobe of the rat pituitary gland is negatively coupled to adenylate cyclase. Life Sci 1982;30(11):963-968. (Pubitemid 12100864)
22. Onali P, Olianas MC, Gessa GL. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Mol Pharmacol 1985;28(2):138-145. (Pubitemid 16244113)
23. Sokoloff P, Martres MP, Schwartz JC. Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. Naunyn Schmiedebergs Arch Pharmacol 1980;315(2):89-102. (Pubitemid 11142907)
24. Ferland L, Meunier H, DiPaolo T, Giguère V, Veilleux R, Labrie F. The pituitary gland: a model for the study of dopaminergic systems. In: Collu R, Ducharme JR, Barbeau A, Tolis G, editors. Brain peptides and hormones. New York: Raven Press; 1981. p. 55-65.
25. Creese I, Morrow AL, Leff SE, Sibley DR, Hamblin MW. Dopamine receptors in the central nervous system. Int Rev Neurobiol 1982;23:255-301.
26. Seeman P. Nomenclature of central and peripheral dopaminergic sites and receptors. Biochem Pharmacol 1982;31(16):2563-2569. (Pubitemid 12046964)
27. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, et al. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J 1989;8(13):4025-4034. (Pubitemid 20066843)
28. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci U S A 1989;86(24):9762-9766. (Pubitemid 20030713)
29. Seeman P, Nam D, Ulpian C, Liu IS, Tallerico T. New dopamine receptor, D2(Longer), with unique TG splice site, in human brain. Brain Res Mol Brain Res 2000;76(1):132-141.
30. Giros B, Martres MP, Sokoloff P, Schwartz JC. [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome.] C R Acad Sci III 1990;311(13):501-508. French.
31. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350(6319):610-614. (Pubitemid 21912282)
32. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992;358(6382):149-152.
33. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993;2(6):767-773. (Pubitemid 23197523)
34. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350(6319):614-619. (Pubitemid 21912283)
35. Kebabian JW, Greengard P. Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science 1971;174(16):1346-1349.
36. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22(23):3099-3108.
37. Niznik HB, Otsuka NY, Dumbrille-Ross A, Grigoriadis D, Tirpak A, Seeman P. Dopamine D1 receptors characterized with [3H]SCH 23390. Solubilization of a guanine nucleotide-sensitive form of the receptor. J Biol Chem 1986;261(18):8397-8406. (Pubitemid 17202719)
38. Niznik HB, Fogel EL, Chen CJ, Congo D, Brown EM, Seeman P. Dopamine D1 receptors of the calf parathyroid gland: identification and characterization. Mol Pharmacol 1988;34(1):29-36.
39. Seeman P. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Synapse 2007;61(12):1013-1018. (Pubitemid 350271782)
40. List SJ, Seeman P. Resolution of the dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions. Proc Natl Acad Sci U S A 1981;78(4):2620-2624. (Pubitemid 11067259)
41. Lazareno S, Nahorski SR. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone. Eur J Pharmacol 1982;81(2):273-285.
42. Grigoriadis D, Seeman P. [3H]-domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986;332(1):21-25. (Pubitemid 16149707)
43. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192(4238):481-483.
44. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980;32(3):229-313.
45. Seeman P, Schaus JM. Receptor tables. In: Drug dissociation constants for neuroreceptors and transporters. Toronto: SZ Research; 1991.
46. Seeman P, Ulpian C, Wreggett KA, Wells JW. Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples. J Neurochem 1984;43(1):221-235. (Pubitemid 14083338)
47. Seeman P, Van Tol HH. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 1995;291(2):59-66.
48. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989;3(1):96-97. (Pubitemid 19042519)
49. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000;20(3):423-451. (Pubitemid 30164887)
50. Seeman P. Antipsychotic drugs, dopamine receptors, and schizophrenia. Clinical Neuroscience Research 2001;1(1-2):53-60. (Pubitemid 33713784)
51. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38.
52. Malmberg A, Jackson DM, Eriksson A, Mohell N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 1993;43(5):749-754.
53. Seeman MV. Pharmacologic features and effects of neuroleptics. Can Med Assoc J 1981;125(8):821-826.
54. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4. Neuropsychopharmacology 1992;7(4):261-284.
55. Seeman P. Glutamate and dopamine components in schizophrenia. J Psychiatry Neurosci 2009;34(2):143-149.
56. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24(2):192-208.
57. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13(9):1102-1107. (Pubitemid 47517511)
58. Seeman P, Guan HC. Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor. Synapse 2009;63(10):935-939.
59. Seeman P. Scholarpedia 2007;2(10):3634. Available from: URL: http://www.scholarpedia.org/article/Dopamine-and-schizophrenia
60. Seeman P, Guan HC. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors. Synapse 2009;63(8):705-709.
61. Seeman P. Glutamate agonists for schizophrenia stimulate dopamine D2High receptors. Schizophr Res 2008;99(1-3):373-374.
62. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538-544.
63. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-293. (Pubitemid 29077120)
64. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008;172:177-197.
65. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997;16(2):93-110. (Pubitemid 27088199)
66. Seeman P, Guan HC. Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia. Synapse 2008;62(11):819-828.
67. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156(6):876-884. (Pubitemid 29260342)
68. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360-369.
69. Zanotti JM, Hervé G, Bellissent-Funel MC. Picosecond dynamics of T and R forms of aspartate transcarbamylase: a neutron scattering study. Biochim Biophys Acta 2006;1764(10):1527-1535. (Pubitemid 44548539)
70. Toews ML, Harden TK, Perkins JP. High-affinity binding of agonists to beta-adrenergic receptors on intact cells. Proc Natl Acad Sci U S A 1983;180(12):3553-3557. (Pubitemid 13063119)
71. Okazaki M, Ferrandon S, Vilardaga JP, Bouxsein ML, Potts JT Jr, Gardella TJ. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A 2008;105(43):16525-16530
72. Hoare SR, Sullivan SK, Pahuja A, Ling N, Crowe PD, Grigoriadis DE. Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands. Peptides 2003;24(12):1881-1897.
73. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985;117(2):690-697. (Pubitemid 15237891)
74. Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol Pharmacol 1983;23(2):295-302.
75. Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR. Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. Synapse 2009;63(6):462-475.
76. Seeman P. Dopamine D2(High) receptors on intact cells. Synapse 2008;62(4):314-318.
77. Imafuku J. The characterization of [3H]sulpiride binding sites in rat striatal membranes. Brain Res 1987;402(2):331-338. (Pubitemid 17005302)
78. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 2006;97(4):1089-1103.
79. Seneca N, Finnema SJ, Farde L, Gulyás B, Wikström HV, Halldin C, et al. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse 2006;59(5):260-269. (Pubitemid 43271734)
80. Finnema SJ, Halldin C, Bang-Andersen B, Gulyás B, Bundgaard C, Wikström HV, et al. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain-a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse 2009;63(5):378-389.
81. McCormick PN, Kapur S, Seeman P, Wilson AA. Dopamine D2 receptor radiotracers [11C](+)-PHNO and [3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 2008;35(1):11-17. (Pubitemid 350298245)
82. Ross SB, Jackson DM. Kinetic properties of the in vivo accumulation of 3H-(-)-N-n-propylnorapomorphine in mouse brain. Naunyn Schmiedebergs Arch Pharmacol 1989;340(1):13-20. (Pubitemid 19192815)
83. Seeman P. Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals. Synapse 2009;63(3):186-192.
84. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 2005;102(9):3513-3518. (Pubitemid 40328076)
85. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006;60(4):319-346. (Pubitemid 44134353)
86. von Zastrow M, Kobilka BK. Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. J Biol Chem 1992;267(5):3530-3538.
87. Insel PA, Mahan LC, Motulsky HJ, Stoolman LM, Koachman AM. Time-dependent decreases in binding affinity of agonists for beta-adrenergic receptors of intact S49 lymphoma cells. A mechanism of desensitization. J Biol Chem 1983;258(22):13597-13605.
88. Yao XJ, Vélez Ruiz G, Whorton MR, Rasmussen SG, Devree BT, Deupi X, et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A 2009; 106(23):9501-9506.
89. Fujita N, Nakahiro M, Fukuchi I, Saito K, Yoshida H. Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor. Brain Res 1985;333(2):231-236. (Pubitemid 15093580)
90. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91(4):415-433. (Pubitemid 17038204)
91. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004;185:196-204.
92. Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005;10(9):877-883.
93. Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil. Synapse 2009;63(8):698-704.
94. Seeman P, McCormick PN, Kapur S. Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [3H](+)PHNO. Synapse 2007;61(5):263-267. (Pubitemid 46412166)
95. Bhardwaj SK, Beaudry G, Quirion R, Levesque D, Srivastava LK. Neonatal ventral hippocampus lesion leads to reductions in nerve growth factor inducible-B mRNA in the prefrontal cortex and increased amphetamine response in the nucleus accumbens and dorsal striatum. Neuroscience 2003;122(3):669-676. (Pubitemid 37410288)
96. King MV, Seeman P, Marsden CA, Fone KC. Increased dopamine D2High receptors in rats reared in social isolation. Synapse 2009;63(6):476-483.
97. Seeman P, Battaglia G, Corti C, Corsi M, Bruno V. Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse 2009;63(3):247-251.
98. Seeman P, Tallerico T, Ko F. Alcohol-withdrawn animals have a prolonged increase in dopamine D2high receptors, reversed by general anesthesia: relation to relapse? Synapse 2004;52(2):77-83.
99. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, et al. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 2007;6(7):628-639. (Pubitemid 47476185)
100. Shuto T, Seeman P, Kuroiwa M, Nishi A. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats. Eur J Neurosci 2008;27(10):2551-2557. (Pubitemid 351781664)
101. Briand LA, Flagel SB, Seeman P, Robinson TE. Cocaine self-administration produces a persistent increase in dopamine D2High receptors. Eur Neuropsychopharmacol 2008;18(8):551-556.
102. Simola N, Morelli M, Seeman P. Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects. Synapse 2008;62(5):394-397. (Pubitemid 351451808)
103. Tassin JP, Torrens Y, Salomon L, Lanteri C, Seeman P. Elevated dopamine D2High receptors in alpha-1b-adrenoceptor knockout supersensitive mice. Synapse 2007;61(7):569-572. (Pubitemid 46753975)
104. Sumiyoshi T, Seeman P, Uehara T, Itoh H, Tsunoda M, Kurachi M. Increased proportion of high-affinity dopamine D2 receptors in rats with excitotoxic damage of the entorhinal cortex, an animal model of schizophrenia. Brain Res Mol Brain Res 2005;140(1-2):116-119. (Pubitemid 41446154)
105. Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. Eur J Neurosci 2003; 18(11):3097-3104.
106. Alttoa A, Seeman P, Kõiv K, Eller M, Harro J. Rats with persistently high exploratory activity have both higher extracellular dopamine levels and higher proportion of D2High receptors in the striatum. Synapse 2009;63(5):443-446.
107. Seeman P, Hall FS, Uhl G. Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 2007;61(7):573-576. (Pubitemid 46753976)
108. Mileson BE, Lewis MH, Mailman RB. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res 1991;561(1):1-10.
109. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to failure over time. J Neurosci 2007;27(11):2979-2986. (Pubitemid 46438984)
110. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008;64(2):145-152.
111. Remington G, Mann S, Kapur S, Seeman P. "Extended" dosing - redefining intermittent antipsychotic therapy: a double-blind trial. Schizophr Bull 2009;35(2):351-352.
112. Seeman P. Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High). Schizophr Res 2009;109(1-3):191-192.
113. Baumeister AA, Francis JL. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 2002;11(3):265-277.
114. Cox BA, Henningsen RA, Spanoyannis A, Neve RL, Neve KA. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. J Neurochem 1992;59(2):627-635.
115. Mansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, Akil H. Site-directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol 1992;227(2):205-214.
116. Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A 1999;96(9):5173-5176. (Pubitemid 29214555)
117. Klein C, Gurvich N, Sena-Esteves M, Bressman S, Brin MF, Ebersole BJ, et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol 2000;47(3):369-373. (Pubitemid 30141848)
118. Grimes DA, Bulman D, George-Hyslop PS, Lang AE. Inherited myoclonus-dystonia: evidence supporting genetic heterogeneity. Mov Disord 2001;16(1):106-110. (Pubitemid 36041122)
119. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 2000;403(6767):274-280. (Pubitemid 30062376)
120. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res 2001;87(2):160-165. (Pubitemid 32195466)
121. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 1994;343(8899):703-704. (Pubitemid 24087850)
122. Glatt SJ, Jönsson EG. The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses. Am J Med Genet B Neuropsychiatr Genet 2006;141 B(2):149-154.
123. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008;40(7):827-834.
124. Glatt SJ, Faraone SV, Tsuang MT. Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol Psychiatry 2003;8(11):911-915. (Pubitemid 37421697)
125. Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, et al. The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophr Res 2005;73(1):31-37. (Pubitemid 39574676)
126. Hänninen K, Katila H, Kampman O, Anttila S, Illi A, Rontu R, et al. Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. Neurosci Lett 2006;407(3):195-198. (Pubitemid 44402872)
127. Ujike H, Katsu T, Okahisa Y, Takaki M, Kodama M, Inada T, et al. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(4):625-629.
128. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006;10(4):515-531.
129. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006;49(4):603-615. (Pubitemid 43221894)
130. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991;5(1):21-33.
131. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978;135(11):1409-1410.
132. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 2005;62(4):371-378. (Pubitemid 40471686)
133. Corripio I, Perez V, Catafau AM, Mena E, Carrio I, Alvarez E. Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage 2006;29(2):662-666. (Pubitemid 43063323)
134. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1(2):133-152.
135. Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci U S A 1989;86(24):10156-10160. (Pubitemid 20030798)
136. Seeman P, Sunahara RK, Niznik HB. Receptor-receptor link in membranes revealed by ligand competition: example for dopamine D1 and D2 receptors. Synapse 1994;17(1):62-64. (Pubitemid 24137234)
137. Surmeier DJ, Eberwine J, Wilson CJ, Cao Y, Stefani A, Kitai ST. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci U S A 1992;89(21):10178-10182.
138. Hu XT, White FJ. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Synapse 1994;17(1):43-61.
139. Braun AR, Laruelle M, Mouradian MM. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J Neural Transm 1997;104(4-5):341-362. (Pubitemid 27379894)
140. Johansson P, Levin E, Gunne L, Ellison G. Opposite effects of a D1 and a D2 agonist on oral movements in rats. Eur J Pharmacol 1987;134(1):83-88. (Pubitemid 17015238)
141. Nanko S, Fukuda R, Hattori M, Sasaki T, Dai XY, Yamaguchi K, et al. Further evidence of no linkage between schizophrenia and the dopamine D3 receptor gene locus. Am J Med Genet 1994;54(3):264-267. (Pubitemid 24292189)
142. Jönsson E, Lannfelt L, Sokoloff P, Schwartz JC, Sedvall G. Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene. Acta Psychiatr Scand 1993;87(5):345-349. (Pubitemid 23134644)
143. Utsunomiya K, Shinkai T, De Luca V, Hwang R, Sakata S, Fukunaka Y, et al. Genetic association between the dopamine D3 gene polymorphism (Ser9Gly) and schizophrenia in Japanese populations: evidence from a case-control study and meta-analysis. Neurosci Lett 2008;444(2):161-165.
144. Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry 2009;66(6):606-615.
145. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999;400(6742):371-375. (Pubitemid 29344203)
146. Lecrubier Y. A partial D3 receptor agonist in schizophrenia. European Neuropsychopharmacology 2003;13(Suppl 4):S167-S168.
147. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005;57(12):1543-1549. (Pubitemid 40805384)
148. Li M, Fletcher PJ, Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 2007;32(2):263-272. (Pubitemid 46106933)
149. Anderson WH, Kuehnle JC, Catanzano DM. Rapid treatment of acute psychosis. Am J Psychiatry 1976;133(9):1076-1078.
150. Carter RG. Psychotolysis with haloperidol. Rapid control of the acutely disturbed psychotic patient. Dis Nerv Syst 1977;38(4):237-239.
151. Glovinsky D, Kirch DG, Wyatt RJ. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 1992;31(9):968-970. (Pubitemid 24118475)
152. Keck PE Jr, Cohen BM, Baldessarini RJ, McElroy SL. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry 1989;146(10):1289- 1292. (Pubitemid 19258476)
153. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006;163(4):743-745. (Pubitemid 44464590)
154. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50(5):369-376. (Pubitemid 23143126)
155. Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007;164(4):630-637. (Pubitemid 46650195)
156. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 1984;225(4663):728-731. (Pubitemid 14054320)
157. Lee T, Seeman P. Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 1980;137(2):191-197. (Pubitemid 10143768)
158. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 1990;47(3):213-219.
159. Nordström AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res 1995;61(2):67-83.
160. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009;34(4):1078-1086.